medigraphic.com
ISSN 1561-3070 (Electronic)

2021, Number 1

<< Back Next >>

Rev Cub Oftal 2021; 34 (1)

Clinical response to treatment with HerberFERON® in patients with basal palpebral carcinoma

Rojas RI, Vigoa AL, Garcìa VY, Bello RI, Duncan RY

Language: Spanish
References: 27
Page: 1-20
PDF size: 407.81 Kb.


ABSTRACT

Objective: To determine the clinical response in patients with basal palpebral carcinoma treated with HeberFERON®. Methods: A descriptive study was carried out in patients with eyelid cell basal carcinoma tried with HeberFERON® in the Cuban Institute of Ophthalmology "Ramón Pando Ferrer" from January 2013 to January 2015. The sample consisted of 10 patients who fulfilled the inclusion criteria. The study variables were: age, sex, skin color, clinical form, tumor diameter, histological subtype of the tumor, as well as the clinical response after treatment of the cases studied. In all the variables, absolute and relative frequencies were calculated.
Results: Male gender and white-skinned subjects predominated. The clinical form ulcerative nodule, poorly differentiated histological tumor subtype, and objective clinical response were present in the patients studied.
Conclusions: In most of the patients a good clinical answer was achieved to the treatment with HeberFERON, which becomes a new non surgical alternative.


REFERENCES

  1. Guzmán R. Dermatología. Atlas, diagnóstico y tratamiento. New York: McGraw-Hill; 2015.

  2. Wu Peggy A, Stern Robert S, Robinson June K, Corona R. Epidemiology, pathogenesis, and clinical features of basal cell carcinoma. Up To Date. Literature review current through; 2019.

  3. Rojas Rondón I, Mendoza Pérez M, Rodríguez Masó S. Concordancia entre el diagnóstico clínico y el anatomopatológico de los tumores malignos del párpado. Rev Cubana Oftalmol. 2019;27(1):79-90.

  4. Rojas Rondón I, Agramonte Centelles IC, Río Torres M. Afecciones palpebrales. La Habana: Editorial Ciencias Médicas; 2018.

  5. Rosales MD, Ascarza AA. Precisión diagnóstica de la evaluación clínica de lesiones palpebrales. Oftalmol Clín Ex. 2017;10(4):124-33.

  6. Piña Y, Piña JJ, Castro AM, Darias C. Dermatoscopia para establecer márgenes quirúrgicos mínimos en la resección de carcinomas basocelulares. Rev Méd Electrón [Internet]. 2018 [acceso: 30/03/2021];40(1). Disponible en: http://www.revmedicaelectronica.sld.cu/index.php/rme/article/view/2130/3704

  7. Telich JE, Monter A, Baldín A, Apellaniz A. Diagnóstico y tratamiento de los tumores malignos de piel. Acta Med Grupo Ang. 2017;15(2):154-60.

  8. Pfeiffer MJ, Pfeiffer N. Valor C. Estudio descriptivo sobre el carcinoma basocelular en el párpado. Arch Soc Esp Oftalmol. 2015;9(9):426-31.

  9. Marzuka AG, Book SE. Basal Cell Carcinoma: Pathogenesis, Epidemiology, Clinical Features, Diagnosis, Histopathology, and Management. Yale J Biol Med. 2015;88(2):167-79.

  10. Bello Rivero I, García Vega Y, Valenzuela Silva C, Bello Álvarez C. J Canc Res Ther Rev. 2013;1(10):235-43.

  11. Anasagasti Angulo L, García Vega Y, Pérez S, López Saura P, Bello Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons, prospective study. AMJ. 2009;9(262):1-12.

  12. García García I, Hernández González I, Díaz Machado A, González Delgado CA, Pérez Rodríguez S, García Vega Y, et al. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha2b and gamma in healthy male volunteers. BMC Pharmacology and Toxicology. 2016 [acceso: 20/06/2019];17(1): [aprox 15 p.]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27923408

  13. García Vega Y, Anasagasti Angulo L, Valenzuela Silva C, Navarro Mestre M, Maribeth Ordóñez S, Acosta Medina D, et al. Retrospective Study of Periocular Non Melanoma Skin Cancer Treated with the Combination of IFN alpha2b and Gamma (HeberPAG). J Clin Exp Ophthalmol. 2015 [acceso: 20/06/2019];6:5:[aprox 15 p.]. Disponible en: https://www.omicsonline.org/open-access/retrospective-study-of-periocular-non-melanoma

  14. Fernández Martori M, Bello Rivero I, Duncan Roberts Y. Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care. Medic Review. 2018;20(1):11-7.

  15. Anasagasti Angulo L, García Vega Y, Collazo S, Jiménez Barban Y, Tijerino Arrieta E, Ballester Caballero Y. HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer. AMJ. 2017;10(6):509-15.

  16. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Asociación Médica Mundial; 2020 [acceso: 20/06/2019]. Disponible en: http://www.wma.net/e/policy/

  17. Therasse P, Arbuck SG, Eisenhaver EA, et al. New Guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer inst. 2000;92(3):205-16.

  18. Rojas Rondón I, Pérez Rodríguez L, Ramírez García LK, Gómez Cabrera CG, Vigoa Aranguren L. Correlación clínica y anátomo-patológica de los tumores palpebrales intervenidos quirúrgicamente en el Servicio de Oculoplastia. Rev Cubana Oftalmol. 2014;27(3):2.

  19. Castillo Menéndez MD, Cabrera Pereda MJ, Díaz de Villegas Álvarez E, Sabatés Martínez M, Herrera Albuquerque D. Correlación clínico-histológica de pacientes operados de cáncer de piel no melanocítico en la provincia de Cienfuegos, año 2001. Rev Cubana Med. 2003;42(3);2.

  20. García Ramírez LK, Ortiz DL, Gómez CG, Vigoa L, Rojas I, Abreu FA. Caracterización clinicopatológica de los tumores malignos palpebrales. Rev Cubana Oftalmol. 2014;27(1):79-90.

  21. Negrín Caceres Y, Cabrera Romero AC, Cárdenas Monzón L, Ferrer Pérez A, Batista Hernández NE. Synergestic effect of combined IFN- Alpha-2b and Gamma treatment for pericular Basal Cell Carcinoma. Rev Mex Oftalmol. 2018;92(3):136-43.

  22. Wong KY, Fife K, Lear JT, Prince RD, Durrani AJ. Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases. Plast Reconstr Surg Glob Open. 2017;5(7):e1424.

  23. Bernia E, Llombart B, Serna Guillén C, Bancalori B, Nagore E, Requena C, et al. Experiencia con Vismodegib en carcinoma basocelular avanzado en centro oncológico. Actas Dermosifiliogr. 2018;109(9):813-20.

  24. Xie P, Lefrancois P. Efficacy, safety, and comparison of sonic Hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. J Am Acad Dermatol. 2018; 79(6):1089-100.

  25. Koelblinger P, Lang R. New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib. Onco Targets Ther. 2018;11:8327-40.

  26. Ruiz Salas V, Espinosa S, Naranjo M. Terapias no quirúrgicas para el carcinoma basocelular. Actas Dermosifiliogr. 2017;108(9): 809-17.

  27. Sociedad Argentina de Dermatología. Consenso sobre carcinoma basocelular y carcinoma espinocelular. Guía de recomendaciones. Buenos Aires: Sociedad Argentina de Dermatología; 2005 [acceso: 20/06/2019]. Disponible en: Disponible en: http://www.sad.org.ar/




2020     |     www.medigraphic.com